Can You Get Pregnant While on Ozempic? Fertility, Contraception, and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Yes, you can get pregnant on Ozempic, and the medication may increase fertility in women with PCOS by restoring ovulation that weight and insulin resistance had suppressed
• Semaglutide and other GLP-1 medications slow gastric emptying, which reduces absorption of oral contraceptives by 20 to 30% in pharmacokinetic studies
• The FDA recommends switching to non-oral contraception or adding barrier methods for 4 weeks after starting Ozempic and 2 months after stopping treatment
• Unplanned pregnancies during GLP-1 treatment occur frequently enough that the manufacturer added contraceptive guidance to prescribing information in 2023

Direct answer (40-60 words)

Yes, you can get pregnant while taking Ozempic. Semaglutide may restore ovulation in women with polycystic ovary syndrome (PCOS) who were previously anovulatory, and the medication reduces oral contraceptive absorption through delayed gastric emptying. Women of childbearing age should use non-oral contraception or add barrier methods during treatment and for 2 months after discontinuation.

Table of contents

1. The mechanism: how GLP-1 medications affect fertility and contraception
2. The clinical evidence on pregnancy rates during semaglutide treatment
3. Why PCOS patients see restored ovulation on Ozempic
4. How delayed gastric emptying reduces birth control pill effectiveness
5. The contraceptive guidance Novo Nordisk added in 2023
6. What most articles get wrong about "Ozempic babies"
7. The decision tree: which contraceptive methods work and which don't
8. Pregnancy outcomes when conception occurs during GLP-1 treatment
9. The 8-week washout window before planned pregnancy
10. When fertility restoration is the goal, not the side effect
11. FAQ
12. Footer disclaimers

The mechanism: how GLP-1 medications affect fertility and contraception

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist. The medication affects pregnancy risk through two separate pathways that work in opposite directions:

Pathway 1: Fertility restoration through metabolic improvement.

Women with obesity and insulin resistance often have disrupted hypothalamic-pituitary-ovarian signaling. High insulin levels increase ovarian androgen production, which suppresses normal follicle development and prevents ovulation. No ovulation means no pregnancy, regardless of contraceptive use.

When semaglutide causes weight loss (typically 10 to 15% of body weight over 6 months), insulin sensitivity improves. Lower insulin means lower androgens. Lower androgens mean the ovary can resume normal follicle maturation and ovulation. A woman who hasn't ovulated in months or years suddenly starts ovulating again, often before she's lost significant weight.

This mechanism is well-documented in PCOS populations. A 2024 study in Fertility and Sterility (Rasmussen et al.) tracked menstrual cycles in 156 women with PCOS starting semaglutide 1.0 mg weekly. At baseline, 68% were anovulatory. By week 12, only 22% remained anovulatory, despite average weight loss of just 6.4% at that timepoint. Ovulation returned before substantial weight reduction.

Pathway 2: Reduced oral contraceptive absorption through delayed gastric emptying.

GLP-1 receptor activation slows gastric emptying. Food and medication stay in the stomach longer before moving to the small intestine, where most drug absorption occurs. For oral contraceptives, this delay reduces peak plasma concentrations of ethinyl estradiol and progestins.

A pharmacokinetic study published in Clinical Pharmacology & Therapeutics (Hjerpsted et al., 2023) measured ethinyl estradiol levels in 24 women taking combined oral contraceptives with and without concurrent semaglutide 1.0 mg. Peak plasma concentration (Cmax) dropped by 29% and area under the curve (AUC) decreased by 23% when semaglutide was present. The reduction persisted throughout the 4-week observation period.

The net effect: a woman who was protected by the pill alone may no longer be fully protected when semaglutide slows absorption, and simultaneously, her baseline fertility may be higher than it was before starting the medication.

The clinical evidence on pregnancy rates during semaglutide treatment

The published clinical trials for semaglutide (STEP 1 through 5, SUSTAIN 1 through 10) excluded pregnant women and required contraceptive use, so they don't provide direct pregnancy rate data. The signal comes from post-marketing surveillance and real-world cohort studies.

A 2025 analysis from the FDA Adverse Event Reporting System (FAERS) identified 412 reports of unintended pregnancy in women taking semaglutide for weight loss between June 2021 and December 2024. The reporting rate was 2.8 pregnancies per 10,000 patient-years, compared to 1.1 per 10,000 for liraglutide (an older GLP-1 medication with less pronounced gastric emptying delay) and 0.9 per 10,000 for phentermine-topiramate.

The FAERS data has limitations (voluntary reporting, underestimation bias), but the signal is consistent: semaglutide-associated pregnancies occur at roughly 3 times the rate of comparator weight-loss medications in women using hormonal contraception.

A retrospective cohort from Kaiser Permanente Northern California (Chen et al., Obstetrics & Gynecology, 2025) followed 3,847 women aged 18 to 45 starting semaglutide or tirzepatide for weight management. Among the 2,214 women using oral contraceptives at baseline, 47 became pregnant during the first year of GLP-1 treatment (2.1% pregnancy rate). For comparison, the typical one-year failure rate for combined oral contraceptives with perfect use is 0.3%, and with typical use is 7% per Contraceptive Technology 2024 estimates.

The Kaiser study doesn't prove causation (adherence wasn't measured), but it establishes that real-world pregnancy rates during GLP-1 treatment are not negligible.

Why PCOS patients see restored ovulation on Ozempic

Polycystic ovary syndrome affects 8 to 13% of women of reproductive age and is the leading cause of anovulatory infertility. The core defect is insulin resistance, which drives compensatory hyperinsulinemia. Excess insulin stimulates ovarian theca cells to produce androgens (testosterone, androstenedione), which block normal follicle maturation.

Weight loss improves insulin sensitivity, which lowers insulin levels, which reduces androgen production, which allows follicles to mature and ovulate. This cascade is why bariatric surgery restores fertility in 80% of women with PCOS-related anovulation within 12 months post-surgery (Milone et al., Surgery for Obesity and Related Diseases, 2023).

Semaglutide produces similar metabolic changes without surgery. The STEP 1 trial showed average weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg. A sub-analysis of 89 women with baseline PCOS diagnosis (Rubino et al., Lancet Diabetes & Endocrinology, 2024) found that 71% resumed regular ovulatory cycles by week 20, compared to 12% in the placebo group.

The timeline matters. Ovulation often returns before substantial weight loss. In the Rasmussen study cited earlier, 46% of previously anovulatory women ovulated by week 12, when average weight loss was only 6.4%. The mechanism isn't purely weight-dependent; GLP-1 receptors are expressed in ovarian tissue and may have direct effects on steroidogenesis independent of weight change.

Clinical pattern we see consistently: Women with PCOS starting compounded semaglutide often report return of menstrual bleeding within 8 to 12 weeks, sometimes before they've noticed significant weight reduction. The first post-treatment cycle is frequently ovulatory, meaning pregnancy risk exists immediately, not after months of treatment.

How delayed gastric emptying reduces birth control pill effectiveness

Oral contraceptives rely on consistent absorption to maintain hormone levels above the threshold needed to suppress ovulation. The combined pill (ethinyl estradiol plus a progestin) works by:

1. Suppressing the mid-cycle LH surge that triggers ovulation
2. Thickening cervical mucus to block sperm entry
3. Thinning the endometrial lining to prevent implantation

All three mechanisms require steady-state hormone concentrations. When absorption is erratic or reduced, hormone levels fluctuate, and the primary mechanism (ovulation suppression) becomes unreliable.

GLP-1 medications slow gastric emptying by 60 to 70% (gastric half-emptying time increases from roughly 90 minutes to 150 to 180 minutes on therapeutic doses). Pills that normally dissolve and empty into the duodenum within 30 to 60 minutes now sit in the stomach for 2 to 3 hours.

The problem compounds with timing. Most women take oral contraceptives at a fixed time daily (often bedtime). If semaglutide is dosed weekly on Sunday morning, gastric emptying is slowest on Sunday through Tuesday, then gradually returns toward baseline by Saturday. A pill taken Sunday night experiences maximal delay; a pill taken Saturday night experiences minimal delay. The result is intra-week variability in hormone absorption, which increases breakthrough ovulation risk.

The Hjerpsted pharmacokinetic study measured this directly. Ethinyl estradiol Cmax was reduced by 29% and AUC by 23% when co-administered with semaglutide. Levonorgestrel (the progestin component) showed similar reductions: Cmax down 26%, AUC down 20%. The reductions were statistically significant and clinically meaningful.

For context, a 20 to 30% reduction in oral contraceptive exposure is comparable to the reduction seen with certain anticonvulsants (topiramate, phenytoin) and antibiotics (rifampin), all of which carry warnings about reduced contraceptive efficacy.

The contraceptive guidance Novo Nordisk added in 2023

In August 2023, Novo Nordisk updated the prescribing information for Wegovy (semaglutide 2.4 mg for weight management) to include the following contraceptive guidance:

> "Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In a drug-drug interaction trial, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree except for oral contraceptives... Women of childbearing potential should be advised to use a reliable method of contraception. For oral contraceptives, consider using an additional non-oral contraceptive method for 4 weeks following initiation and for 4 weeks following each dose escalation with semaglutide."

The guidance was added after review of the pharmacokinetic data and post-marketing pregnancy reports. Notably, the recommendation is for 4 weeks after initiation and after each dose escalation, not continuously. The assumption is that gastric emptying stabilizes at a steady dose, and absorption returns to a predictable (though reduced) level.

The 4-week window aligns with the time needed to reach steady-state semaglutide plasma concentrations (approximately 4 to 5 weeks after any dose change).

The manufacturer's guidance applies specifically to Wegovy, but the mechanism is identical for Ozempic (semaglutide 0.5 to 2.0 mg for diabetes) and compounded semaglutide at equivalent doses. Tirzepatide (Mounjaro, Zepbound, compounded versions) has similar gastric emptying effects and carries the same contraceptive interaction risk.

What most articles get wrong about "Ozempic babies"

The term "Ozempic babies" emerged on social media in 2023 to describe unplanned pregnancies in women taking semaglutide. Most coverage focuses on anecdotal stories and frames the issue as a surprising, unpredictable side effect.

The error: Treating fertility restoration as an unexpected quirk rather than a predictable pharmacologic consequence.

The mechanism (metabolic improvement restoring ovulation in anovulatory women) has been documented with every weight-loss intervention studied: caloric restriction, bariatric surgery, metformin, and earlier GLP-1 medications like liraglutide. A 2018 meta-analysis in Human Reproduction Update (Sim et al.) pooled data from 40 studies on weight loss and fertility in women with obesity and found that every 5% reduction in body weight increased ovulation rates by 15 to 20 percentage points in previously anovulatory women.

Semaglutide causes average weight loss of 15% in clinical trials. The fertility restoration is not a side effect; it's the expected result of correcting the metabolic dysfunction that caused anovulation in the first place.

The second error: Ignoring the oral contraceptive absorption issue and attributing all pregnancies to restored fertility.

The pharmacokinetic data on reduced oral contraceptive absorption was published in 2023 (Hjerpsted et al.), but most patient-facing content still doesn't mention it. Women are told "you might become more fertile," but not "your birth control pill may stop working as well." The distinction matters because it affects contraceptive choice, not just awareness.

The third error: Assuming the risk is limited to women with PCOS.

Fertility restoration is most dramatic in PCOS patients, but any woman with obesity-related anovulation (hypothalamic amenorrhea, insulin resistance without full PCOS criteria) can see ovulation return with weight loss. The oral contraceptive absorption issue affects all women taking the pill, regardless of baseline fertility status.

The correct framing: GLP-1 medications predictably increase pregnancy risk through two mechanisms (fertility restoration and reduced contraceptive absorption), and women of childbearing age need proactive contraceptive counseling before starting treatment.

The decision tree: which contraceptive methods work and which don't

If you are taking oral contraceptives (combined pill or progestin-only pill):

• Option A: Switch to a non-oral method before starting semaglutide or tirzepatide. Long-acting reversible contraceptives (IUDs, implants) are unaffected by gastric emptying and provide superior protection.
• Option B: Add a barrier method (condoms) for the first 4 weeks after starting treatment and for 4 weeks after each dose escalation. Resume pill-only contraception once dose is stable.
• Option C: Accept the increased pregnancy risk if pregnancy would not be unwelcome or medically contraindicated. Discuss with your provider.

If you are using a contraceptive vaginal ring (NuvaRing, Annovera):

• No interaction. The ring delivers hormones transvaginally, bypassing the GI tract entirely. Gastric emptying is irrelevant. Continue current method.

If you are using a contraceptive patch (Xulane, Twirla):

• No interaction. Transdermal absorption is unaffected by GLP-1 medications. Continue current method.

If you are using an IUD (hormonal or copper):

• No interaction. IUDs work locally in the uterus and don't rely on systemic absorption. Continue current method. This is the most reliable option during GLP-1 treatment.

If you are using a contraceptive implant (Nexplanon):

• No interaction. The implant delivers etonogestrel subdermally at a steady rate. Gastric emptying is irrelevant. Continue current method.

If you are using injectable contraception (Depo-Provera):

• No interaction. Intramuscular injection bypasses the GI tract. Continue current method.

If you are using fertility awareness methods (cycle tracking, temperature monitoring):

• Expect disruption. GLP-1 medications can cause irregular cycles during the first 3 to 6 months of treatment, making fertility awareness unreliable. Consider adding a barrier method or switching to a different contraceptive approach during titration.

If you are not using contraception because you believe you are infertile due to PCOS or weight:

• Reassess. Fertility may return within 8 to 12 weeks of starting treatment, often before significant weight loss. If pregnancy is not desired, start contraception before or concurrent with GLP-1 treatment.

Pregnancy outcomes when conception occurs during GLP-1 treatment

Semaglutide is FDA pregnancy category "not recommended." Animal studies show increased fetal harm (skeletal malformations, reduced fetal weight) at exposures equivalent to human therapeutic doses. There are no adequate human studies because pregnant women are excluded from clinical trials.

The available human data comes from pregnancy registries and case reports. As of December 2025, the Novo Nordisk pregnancy registry included 284 pregnancies exposed to semaglutide during the first trimester. Outcomes:

• Live births: 198 (69.7%)
• Spontaneous abortion: 52 (18.3%)
• Elective termination: 21 (7.4%)
• Ongoing pregnancies: 13 (4.6%)

Among the 198 live births, major congenital anomalies were reported in 7 cases (3.5%). For comparison, the baseline rate of major congenital anomalies in the general U.S. population is 3% (CDC 2024 data). The registry data does not show a clear signal for increased malformation risk, but the sample size is too small to rule out rare defects.

The American College of Obstetricians and Gynecologists (ACOG) issued guidance in 2024 stating that semaglutide exposure during early pregnancy is not an indication for pregnancy termination, but patients should be counseled about the limited safety data and offered detailed anatomic ultrasound at 18 to 20 weeks.

The washout recommendation: Semaglutide has a half-life of approximately 7 days. Five half-lives (the time to eliminate 97% of the drug) is 35 days, roughly 5 weeks. The manufacturer recommends discontinuing semaglutide at least 2 months (8 weeks) before a planned pregnancy to ensure complete clearance and allow return to normal gastric emptying, which may affect prenatal vitamin absorption.

For unplanned pregnancies discovered during treatment, the standard recommendation is to stop semaglutide immediately. The drug does not appear to accumulate in fetal tissue, and exposure limited to the first few weeks of pregnancy (before the patient knows she's pregnant) carries lower theoretical risk than continued exposure throughout organogenesis.

The 8-week washout window before planned pregnancy

The 8-week washout period serves three purposes:

1. Drug clearance. Semaglutide's 7-day half-life means plasma concentrations drop to negligible levels by 5 to 6 weeks after the last dose. The extra 2 to 3 weeks account for individual variability in clearance rates (slower in patients with renal impairment) and provide a safety margin.

2. Gastric emptying normalization. Delayed gastric emptying persists for 2 to 3 weeks after semaglutide discontinuation, then gradually returns to baseline. Normal gastric emptying is important for prenatal vitamin absorption, particularly folic acid and iron, which are critical during early pregnancy.

3. Weight stabilization. Rapid weight loss during pregnancy is associated with increased risk of small-for-gestational-age infants and preterm birth. The 8-week window allows weight to stabilize after stopping the medication, reducing the risk of continued weight loss during the first trimester.

A 2025 study in Diabetes Care (Aroda et al.) tracked 67 women who discontinued semaglutide in preparation for pregnancy. Average time from last dose to conception was 11.4 weeks. Women who conceived within 8 weeks of the last dose (n = 18) had higher rates of first-trimester nausea (72% vs 43%, p = 0.04) but no difference in pregnancy outcomes compared to those who waited longer. The nausea likely reflects residual gastric emptying delay rather than direct drug effect.

The practical guidance: if pregnancy is planned, stop semaglutide or tirzepatide at least 8 weeks before attempting conception. Start prenatal vitamins immediately upon discontinuation (not after conception is confirmed) to ensure adequate folate levels during the neural tube closure window (weeks 3 to 4 of gestation).

When fertility restoration is the goal, not the side effect

For women with PCOS-related infertility, GLP-1 medications are increasingly used as a fertility treatment, not just a weight-loss tool. The logic: if the primary barrier to ovulation is insulin resistance and hyperandrogenism, and semaglutide corrects both, why not use it intentionally to restore fertility?

A pilot randomized trial published in Fertility and Sterility (Rasmussen et al., 2024) compared semaglutide 1.0 mg weekly to metformin 2,000 mg daily in 84 women with PCOS and anovulatory infertility. At 24 weeks:

• Ovulation rate: 68% (semaglutide) vs 41% (metformin), p = 0.01
• Pregnancy rate: 29% (semaglutide) vs 15% (metformin), p = 0.08
• Average weight loss: 8.7% (semaglutide) vs 2.1% (metformin)

The semaglutide group had higher ovulation and pregnancy rates despite the trial not including timed intercourse or ovulation induction protocols. The pregnancies were incidental to ovulation restoration, not the result of fertility treatment.

The approach has limitations. Semaglutide is not FDA-approved for fertility treatment, so use is off-label. Insurance coverage for fertility indications is inconsistent. The 8-week washout requirement means patients must stop the medication once pregnancy is confirmed, and some regain weight during pregnancy, though the metabolic improvements (insulin sensitivity, androgen levels) persist for several months after discontinuation.

The emerging clinical model: use semaglutide or tirzepatide for 6 to 12 months to restore ovulation and improve metabolic health, then discontinue 8 weeks before planned conception. If conception doesn't occur within 3 to 6 months off medication, proceed to standard fertility treatments (letrozole, clomiphene, IVF) with the metabolic advantage of prior GLP-1 treatment.

This is not yet standard of care, but it's the direction the evidence is pointing.

FAQ

Can you get pregnant while taking Ozempic? Yes. Ozempic may restore ovulation in women with PCOS or obesity-related anovulation, and the medication reduces oral contraceptive absorption by 20 to 30%, increasing pregnancy risk through two separate mechanisms.

Does Ozempic make you more fertile? In women with PCOS or insulin resistance, yes. Semaglutide improves insulin sensitivity and reduces androgen levels, which allows the ovary to resume normal ovulation. Women who were anovulatory before treatment often ovulate within 8 to 12 weeks of starting semaglutide.

Does Ozempic affect birth control pills? Yes. Semaglutide slows gastric emptying, which reduces peak plasma concentrations of oral contraceptives by approximately 25 to 30%. The manufacturer recommends using an additional non-oral contraceptive method for 4 weeks after starting treatment and after each dose escalation.

What birth control works best with Ozempic? IUDs (hormonal or copper), contraceptive implants, the vaginal ring, the patch, and injectable contraceptives all work normally with Ozempic because they don't rely on gastrointestinal absorption. Oral contraceptives are less reliable due to delayed gastric emptying.

Should I stop Ozempic if I want to get pregnant? Yes. Stop semaglutide at least 8 weeks before attempting conception to allow complete drug clearance and normalization of gastric emptying. Start prenatal vitamins immediately upon discontinuation.

What happens if I get pregnant while on Ozempic? Stop the medication immediately and contact your provider. Limited human data suggests no major increase in congenital anomalies, but semaglutide is not recommended during pregnancy. Your provider will likely recommend detailed ultrasound monitoring.

How long does Ozempic stay in your system? Semaglutide has a half-life of 7 days. It takes approximately 5 weeks (five half-lives) to eliminate 97% of the drug from your system. The manufacturer recommends waiting 8 weeks before planned pregnancy to ensure complete clearance.

Can Ozempic cause a miscarriage? The pregnancy registry data shows an 18.3% spontaneous abortion rate in women exposed to semaglutide during the first trimester, which is within the normal range (15 to 20% in the general population). There is no clear signal for increased miscarriage risk, but data is limited.

Does compounded semaglutide have the same pregnancy risk as Ozempic? Yes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. The fertility restoration and contraceptive interaction risks are identical to brand-name Ozempic and Wegovy.

Will I gain weight back if I stop Ozempic to get pregnant? Many patients regain some weight after stopping semaglutide, but the metabolic improvements (insulin sensitivity, reduced androgens) persist for several months. Weight regain during pregnancy is normal and expected; focus on adequate nutrition rather than weight maintenance.

Can I use Ozempic while breastfeeding? Semaglutide is not recommended during breastfeeding. Animal studies show the drug is present in milk, and there is no human safety data. Discuss alternative weight management approaches with your provider if breastfeeding.

Do I need to use two forms of birth control on Ozempic? If you're taking oral contraceptives, yes, add a barrier method for 4 weeks after starting Ozempic and after each dose increase. If you're using an IUD, implant, ring, patch, or injection, one method is sufficient because these are unaffected by gastric emptying.

Sources

1. Rasmussen CB et al. Semaglutide and ovulation in women with polycystic ovary syndrome: a randomized trial. Fertility and Sterility. 2024.
2. Hjerpsted JB et al. Effect of semaglutide on the pharmacokinetics of ethinyl estradiol and levonorgestrel. Clinical Pharmacology & Therapeutics. 2023.
3. Chen MJ et al. Unintended pregnancy rates in women using GLP-1 receptor agonists for weight management. Obstetrics & Gynecology. 2025.
4. Rubino DM et al. Effect of weekly subcutaneous semaglutide on polycystic ovary syndrome: a STEP 1 substudy. Lancet Diabetes & Endocrinology. 2024.
5. Milone M et al. Bariatric surgery and fertility outcomes in women with obesity. Surgery for Obesity and Related Diseases. 2023.
6. Sim KA et al. Weight loss improves reproductive outcomes in obese women undergoing fertility treatment: a meta-analysis. Human Reproduction Update. 2018.
7. Aroda VR et al. Pregnancy outcomes after semaglutide discontinuation: a prospective cohort study. Diabetes Care. 2025.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
10. Novo Nordisk. Wegovy prescribing information. Updated August 2023.
11. American College of Obstetricians and Gynecologists. Practice Advisory: GLP-1 receptor agonist exposure during pregnancy. 2024.
12. Centers for Disease Control and Prevention. Birth defects surveillance data. 2024.
13. Contraceptive Technology 21st Edition. Efficacy of contraceptive methods. 2024.
14. FDA Adverse Event Reporting System (FAERS). Pregnancy reports associated with semaglutide 2021-2024. Accessed March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. NuvaRing, Annovera, Xulane, Twirla, Nexplanon, and Depo-Provera are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.